ArticleEmerging microbes & infections2023
A novel class of broad-spectrum active-site-directed 3C-like protease inhibitors with nanomolar antiviral activity against highly immune-evasive SARS-CoV-2 Omicron subvariants.
Open access · goldAbstract read
In one paragraph
Article in Emerging microbes & infections, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- TMPRSS2 inhibitors with broad-spectrum efficacy against SARS-CoV-2 (JN.1) and influenza A (H1N1) viruses protect mice from influenza A infection.Emerging microbes & infections · 2026Article
- Drug combination treatment as a strategy for inhibiting human adenovirus replication.Antiviral research · 2026Article
- A reversible broad-spectrum antiviral targets the human V-ATPase VResearch square · 2026Article
- Pharmacokinetics, pathology and efficacy of SARS-CoV-2 main protease inhibitor VPC285785 in a murine model of coronavirus infection.Scientific reports · 2026Article
- Discovery of Coronavirus Main Protease Inhibitors with Enhanced Brain Exposure and Potent Oral Efficacy in SARS-CoV-2 and MERS Infection Models.Journal of medicinal chemistry · 2026Article
- Functional and Structural Characterization of Treatment-Emergent Nirmatrelvir Resistance Mutations at Low Frequencies in the Main Protease (Mpro) Reveals a Unique Evolutionary Route for SARS-CoV-2 to Gain Resistance.The Journal of infectious diseases · 2025Article
- Review
- Exploring anti-SARS-CoV-2 natural products: dual-viral target inhibition by delphinidin and the anti-coronaviral efficacy of deapio platycodin D.Natural products and bioprospecting · 2025Article
- Potential Broad-Spectrum Antiviral Agents: A Key Arsenal Against Newly Emerging and Reemerging Respiratory RNA Viruses.International journal of molecular sciences · 2025Review
- Revisiting the potential of natural antimicrobial peptides against emerging respiratory viral disease: a review.3 Biotech · 2025Review
- Review
- On the origins of SARS-CoV-2 main protease inhibitors.RSC medicinal chemistry · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 3 institutions in 1 country.
Jimena Pérez-VargasDepartment of Microbiology and Immunology, Life Sciences Institute, University of British Columbia, Vancouver, Canada.ORCID 0000-0002-4337-7903
Liam J WorrallDepartment of Biochemistry and Molecular Biology and Centre for Blood Research, University of British Columbia, Vancouver, Canada.ORCID 0000-0003-4966-7175
Andrea D OlmsteadDepartment of Microbiology and Immunology, Life Sciences Institute, University of British Columbia, Vancouver, Canada.ORCID 0000-0002-1110-1291
Anh-Tien TonVancouver Prostate Centre, University of British Columbia, Vancouver, Canada.ORCID 0000-0001-7418-6563
Jaeyong LeeDepartment of Biochemistry and Molecular Biology and Centre for Blood Research, University of British Columbia, Vancouver, Canada.
Ivan VillanuevaDepartment of Microbiology and Immunology, Life Sciences Institute, University of British Columbia, Vancouver, Canada.ORCID 0000-0002-9325-731X
Connor A H ThompsonDepartment of Microbiology and Immunology, Life Sciences Institute, University of British Columbia, Vancouver, Canada.
Svenja DudekDepartment of Microbiology and Immunology, Life Sciences Institute, University of British Columbia, Vancouver, Canada.
Siobhan EnnisFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.ORCID 0000-0002-0105-8269
Jason R SmithVancouver Prostate Centre, University of British Columbia, Vancouver, Canada.ORCID 0000-0001-7380-2192
Tirosh ShapiraDepartment of Microbiology and Immunology, Life Sciences Institute, University of British Columbia, Vancouver, Canada.
Joshua De GuzmanDepartment of Microbiology and Immunology, Life Sciences Institute, University of British Columbia, Vancouver, Canada.
Shutong GangDepartment of Microbiology and Immunology, Life Sciences Institute, University of British Columbia, Vancouver, Canada.
Fuqiang BanVancouver Prostate Centre, University of British Columbia, Vancouver, Canada.
Marija VuckovicDepartment of Biochemistry and Molecular Biology and Centre for Blood Research, University of British Columbia, Vancouver, Canada.ORCID 0000-0002-0452-8270
Michael BieleckiDepartment of Chemistry, Simon Fraser University, Burnaby, Canada.
Suzana KovacicDepartment of Chemistry, Simon Fraser University, Burnaby, Canada.
Calem KenwardDepartment of Biochemistry and Molecular Biology and Centre for Blood Research, University of British Columbia, Vancouver, Canada.ORCID 0000-0002-3771-0044
Christopher Yee HongDepartment of Microbiology and Immunology, Life Sciences Institute, University of British Columbia, Vancouver, Canada.
Danielle G GordonDepartment of Microbiology and Immunology, Life Sciences Institute, University of British Columbia, Vancouver, Canada.
Paul N LevettBritish Columbia Centre for Disease Control Public Health Laboratory, Vancouver, Canada.ORCID 0000-0001-6854-1776
Mel KrajdenBritish Columbia Centre for Disease Control Public Health Laboratory, Vancouver, Canada.
Richard LeducDepartment of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Canada.ORCID 0000-0001-6854-8003
Pierre-Luc BoudreaultDepartment of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Canada.ORCID 0000-0002-2032-7970
Masahiro NiikuraFaculty of Health Sciences, Simon Fraser University, Burnaby, Canada.ORCID 0000-0001-6611-8616
Mark PaetzelDepartment of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, Canada.ORCID 0000-0002-7408-5487
Robert N YoungDepartment of Chemistry, Simon Fraser University, Burnaby, Canada.ORCID 0000-0002-8235-6080
Artem CherkasovVancouver Prostate Centre, University of British Columbia, Vancouver, Canada.ORCID 0000-0002-1599-1439
Natalie C J StrynadkaDepartment of Biochemistry and Molecular Biology and Centre for Blood Research, University of British Columbia, Vancouver, Canada.ORCID 0000-0002-4058-9425
François JeanDepartment of Microbiology and Immunology, Life Sciences Institute, University of British Columbia, Vancouver, Canada.ORCID 0000-0002-6148-7460
University of British Columbia · CASimon Fraser University · CAUniversité de Sherbrooke · CA
Funding
High-Speed High-Sensitivity Detector for X-ray Micro-Crystallography at GM/CA@APSS10OD012289 · OD · UNIVERSITY OF CHICAGO · PI FISCHETTI, ROBERT F. · 2014 to 2014
$2.0MNIH HHS S10 OD012289
Abstract
Antivirals with broad coronavirus activity are important for treating high-risk individuals exposed to the constantly evolving SARS-CoV-2 variants of concern (VOCs) as well as emerging drug-resistant variants. We developed and characterized a novel class of active-site-directed 3-chymotrypsin-like protease (3CLpro) inhibitors (
Indexed as
COVID-19Hepatitis C, ChronicAntiviral AgentsBenzothiazolesDrug CombinationsHumansLactamsLeucineNitrilesProlineProtease InhibitorsRitonavirSARS-CoV-2Sulfonamides(2S)-N-((2S)-1-(((2S)-1-(1,3-benzothiazol-2-yl)-5-(diaminomethylideneamino)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-(methanesulfonamido)pentanediamide)Antiviral AgentsBenzothiazolesDrug CombinationsLactamsLeucinenirmatrelvir and ritonavir drug combinationNitrilesProlineProtease InhibitorsRitonavirSulfonamides3CLpro inhibitorcombination therapycomputer-aided drug designSARS-CoV-2 3CLproSARS-CoV-2 Omicron subvariants
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.